CORAL SPRINGS, FL--(Marketwired - Apr 22, 2014) - Nutra Pharma Corp. (
"With the nation focused on the treatment of chronic pain, especially for returning military veterans, our specially formulated version of Nyloxin should go a long way to effectively managing chronic pain symptoms for many of our wounded warriors," stated Rik J Deitsch, CEO of Nutra Pharma. "By securing a GSA-MAS contract, we can effectively distribute our products directly to various agencies and health departments at set government pricing," he continued. "It is our plan to complete the GSA application process and begin actively marketing Nyloxin, Nyloxin Extra Strength and Nyloxin Military Strength through the GSA in the next few months," he concluded.
Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain. Nutra Pharma announced last year that they would be launching their strongest version of the product, Nyloxin® Military Strength, for distribution to the US Military and other Governmental Agencies.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Marketing through the GSA should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.